Lukas Biomedical (ROCO:6814) Operating Margin %: -43.74% (As of Dec. 2025)


ROCO:6814 Lukas Biomedical Inc ROCO:6814
66 GF Score
Price NT$24.50
GF Value NT$21.85
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Lukas Biomedical Operating Margin %?

Lukas Biomedical ROCO:6814 -4.30% 66 Operating Margin % is -43.74% as of Dec. 2025. GuruFocus rates ROCO:6814 with a GF Score™ of 66/100 and a GF Value™ of NT$21.85 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 944 Biotechnology companies, Lukas Biomedical ranks better than 55.61% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. Lukas Biomedical's Operating Income for the six months ended in Dec. 2025 was NT$-40.1 Mil. Lukas Biomedical's Revenue for the six months ended in Dec. 2025 was NT$91.6 Mil. Therefore, Lukas Biomedical's Operating Margin % for the quarter that ended in Dec. 2025 was -43.74%.

Warning Sign:

Lukas Biomedical Inc operating margin has been in a 5-year decline. The average rate of decline per year is -48.6%.

The historical rank and industry rank for Lukas Biomedical's Operating Margin % or its related term are showing as below:

ROCO:6814' s Operating Margin % Range Over the Past 10 Years
Min: -48.43   Med: -22.54   Max: -1.84
Current: -45.21


ROCO:6814's Operating Margin % is ranked better than
55.61% of 944 companies
in the Biotechnology industry
Industry Median: -86.83 vs ROCO:6814: -45.21

Lukas Biomedical's 5-Year Average Operating Margin % Growth Rate was -48.60% per year.

Lukas Biomedical's Operating Income for the six months ended in Dec. 2025 was NT$-40.1 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-81.1 Mil.

Warning Sign:

Lukas Biomedical Inc has never been profitable in the past 3 years. It lost money every year.


Lukas Biomedical  (ROCO:6814) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Lukas Biomedical Operating Margin % Related Terms


Lukas Biomedical Operating Margin % Historical Data

* Premium members only.

The historical data trend for Lukas Biomedical's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lukas Biomedical Operating Margin % Chart

Lukas Biomedical Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Operating Margin %
Get a 7-Day Free Trial -28.07 -26.28 -18.79 -48.43 -45.21

Lukas Biomedical Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -26.92 -39.94 -57.39 -46.74 -43.74

ROCO:6814 vs VRTX, REGN, ALNY: Operating Margin % Comparison

For the Biotechnology subindustry, Lukas Biomedical's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lukas Biomedical Operating Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lukas Biomedical's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Lukas Biomedical's Operating Margin % falls into.


ROCO:6814
66GF Score
Lukas Biomedical Inc ROCO:6814
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lukas Biomedical Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Lukas Biomedical's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (A: Dec. 2025 ) / Revenue (A: Dec. 2025 )
=-81.147 / 179.493
=-45.21 %

Lukas Biomedical's Operating Margin % for the quarter that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2025 ) / Revenue (Q: Dec. 2025 )
=-40.057 / 91.575
=-43.74 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of -43.74% mean?
Lukas Biomedical (ROCO:6814) has a Operating Margin % of -43.74% as of Dec. 2025. Operating margin is the ratio of total operating income to net sales. View historical data on Lukas Biomedical and its competitors. According to the industry distribution chart, Lukas Biomedical ranks #419 out of 944 companies in the Biotechnology industry, placing it in the top 44.4%.
Is Lukas Biomedical's Operating Margin % too high?
Lukas Biomedical's current Operating Margin % is -43.74%. Based on the distribution chart, Lukas Biomedical ranks #419 out of 944 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Lukas Biomedical has a GF Score™ of 66/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lukas Biomedical's Operating Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lukas Biomedical ranks #419 out of 944 companies for Operating Margin %. This puts Lukas Biomedical in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Lukas Biomedical and its competitors. Lukas Biomedical's current Operating Margin % is -43.74%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lukas Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Lukas Biomedical (ROCO:6814) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$21.85, compared to a current price of NT$24.50 — trading 12.1% above its estimated fair value. The current Operating Margin % is -43.74%. Lukas Biomedical's overall GF Score™ is 66/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Lukas Biomedical (ROCO:6814), the current Operating Margin % is -43.74% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lukas Biomedical (ROCO:6814) Overvalued in 2026?

Based on GuruFocus' analysis, Lukas Biomedical stock appears to be overvalued. The current stock price of NT$24.50 is trading 12.1% above its estimated GF Value™ of NT$21.85. GuruFocus considers Lukas Biomedical to be Modestly Overvalued.

Key valuation signals for ROCO:6814:

  • Operating Margin %: -43.74%
  • GF Value™: NT$21.85 vs. price of NT$24.50 (12.1% above fair value)
  • GF Score™: 66/100 with 7 warning signs

No single metric tells the full story. See the ROCO:6814 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Lukas Biomedical Business Description

Address No. 14-16, Zhongxiao Road, 1st Floor, Banqiao District, New Taipei City, TWN, 220
Lukas Biomedical Inc. is engaged in researching and developing immunotherapy for cancer treatment technologies. The company's main business activities include developing immunocellular therapy, leasing and selling medical equipment, and selling biotech beauty products.
66GF Score

Get the complete analysis for ROCO:6814

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$24.50
Price
NT$21.85
GF Value